Abstract
Background: Improving the awareness of the public about the body weight and the body mass index (BMI) criteria is very important as increased body weight may be associated with an increased risk for many dangerous diseases and health complications. Propranolol is generally prescribed for tachycardia while its most common side effects are bradycardia and masking hypoglycemia.
 Case Presentation: A tachycardia was diagnosed in a young overweight woman and treated successfully with propranolol but this treatment, unpredictably, was associated with a rapid increase in the weight that classified her as obese.
 Discussion: The physical (body weight and heart rate) and the biochemical (blood glucose level) monitoring and analysis including the lifestyle provided a deeper insight into the principal details and helped to design a personalized treatment protocol. 
 Conclusion: A therapeutic dose of propranolol could be linked to uncommon mounting weight change which was associated with a decrease in the blood glucose level and an appetite enhancement.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Advances in Medical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
